Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
The robotic cardiac procedure between Guyana and India, established a new benchmark in global telesurgery across nearly 20,000 kilometres
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Exclusive partnership to expand access to high-quality seamless anodized aluminium packaging for sterile APIs and pharmaceutical products across India.
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
The facility sets a new benchmark in respiratory diagnostics
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
